Adafosbuvir

August 31, 2016 By Mark Terry , BioSpace.com Breaking News Staff Stockholm, Sweden - Medivir AB announced today that it plans to split the company into two independent companies. Originally proposed in June, one of the entities would own Medivir’s commercial products portfolio. That group of drugs including a hepatitis C drug, Olysio, for which it has a partnership with Johnson & Johnson . It also has a batch of drugs sold regionally that it picked up when it acquired BioPhausia in 2011. This first company is expected to be listed on the Nasdaq’s First North Premium. The second company would be an independent biotech company that has MIV-711, a cathepsin K inhibitor the company is developing in a Phase II clinical trial for osteoarthritis. MIV-711 is the only drug in the Medivir clinical pipeline except for a Johnson & Johnson trial of Olysio as part of a triple combination treatment. That trial was announced in May, and is a Phase IIb trial. It is evaluating the efficacy, safety and pharmacokinetics of AL-335, odalasvir and simeprevir in HCV patients. It will involve about 400 patients. However, it does have MIV-802, a nucleotide NS5B polymerase inhibitor, in preclinical development. Earlier this month Medivir licensed exclusive rights to the hepatitis C drug from Boston-based Trek Therapeutics. Trek holds the rights to develop and commercialize the drug globally, excluding China, Taiwan, Hong Kong and Macau. BioPhausia, a Medivir subsidiary, holds commercial rights in the Nordics and specific Western European countries. Medivir is eligible for various developmental milestones, as mid-teen royalties. “We are pleased to have Trek Therapeutics as a partner with their deep knowledge of HCV drug development,” said Niklas Prager , Medivir’s chief executive officer, in a statement, “and their mission to make competitive treatments accessible to world populations.” In addition to its HCV work, Medivir is developing therapeutics for HIV, respiratory syncytial virus, and hepatocellular carcinoma. So far they are all in preclinical development. Medivir stated that, “The objective of the separation is to visualize the value of both the commercial operations and the pharmaceutical projects that make up the R&D portfolio.” It hopes to complete the breakup before the end of the year. Medivir is currently trading for 65.75 SEK (Swedish Krona). Shares traded on Nov. 16, 2015 for 79.25 SEK, and dropped to 47.60 SEK on May 16, 2016, before it began to climb again. Olysio is facing very stiff competition from Gilead Sciences ’s own hepatitis C franchise, which has had a major affect on Medivir stock. Overall, investors appear to be happy with the idea of the split. The original announcement pushed it up by about 30 percent, and since it announced confirmation of the split, it’s gone up another 6 percent. The new company’s success probably depends on MIV-711. Medivir indicates it expects a data readout from the Phase II trial in the second half of 2017. They have a history of outlicensing drugs after Phase II, so if the new company continues with that strategy, it will have an effect on the company’s mid-year status. At this time, Medivir hasn’t disclosed financial information about the split.

October 23, 2015 By Mark Terry , BioSpace.com Breaking News Staff The U.S. Food and Drug Administration (FDA) warned today that Chicago-based AbbVie ’s Viekira Pak and Technivie, for hepatitis C (HCV), can cause serious liver injury in patients that have underlying advanced liver disease. The agency will require AbbVie to add additional safety labeling. AbbVie announced , as a result, that the labeling has been changed from “not recommended in Child Pugh B patients” to a label that indicates the drugs are contraindicated in patients with Child-Pugh B cirrhosis. Patients with Child-Pugh C have always been contraindicated for the drugs. The FDA warning came after seven patients on the drugs died from liver failure. “Most patients with these severe outcomes had evidence of advanced cirrhosis prior to initiating therapy,” said AbbVie spokeswoman Jackie Finley in an email to BloombergBusiness. “Estimates of frequency cannot be made and a causal relationship between treatment and these events has not been established.” In its alert, the FDA noted that although the direct connection was difficult to determine, some of patients’ symptoms stopped when they ceased taking the drugs. The labels on Viekira Pak, which was approved by the FDA in 2014, already indicated the drug wasn’t recommended for patients with serious liver disease. The hepatitis C treatment market has been a hot one the last year or so, as AbbVie went head-to-head in a price war with Gilead Sciences, Inc. and its Sovaldi and Harvoni, which currently lead the market. Johnson & Johnson plans to start a Phase II trial that will combine its HCV drug Olysio with two other HCV drugs, AL-335 and ACH-3012 that J&J acquired through the acquisition of Alios BioPharma and through a collaboration deal with Achillion Pharmaceuticals, Inc. . Harvoni, Sovaldi, Viekira Pak, and Olysio are very effective HCV drugs, although Harvoni and Sovaldi, generally speaking, are probably a little bit better, and dominate the market. Viekira Pak appears to be having some side effects issues in comparison, although is still a very effective drug. J&J hopes its new cocktail of drugs will cut the treatment time in half, from about 12 weeks to six. Because all of these drugs are very expensive, but largely effective, the ability to cut the treatment in time would be very appealing to patients and insurance companies. A 12-week course of Sovaldi runs about $84,000, and Harvoni costs about $94,500. Viekira Pak is priced at about $83,320 for a 12-week regimen. Olysio runs about $66,360 for a 12-week course of treatment. Express Scripts Holding Co. , inked an exclusive distribution deal with AbbVie , part of a pricing negotiation to receive a discount on Viekira Pak. In light of the new safety warnings, Express Scripts Inc. spokesman Brian Henry told Bloomberg that it will evaluate the FDA warning “to determine if any additional action is required.” Asthika Goonewardene , an analyst with Bloomberg Intelligence, indicated that Gilead ’s drugs and AbbVie ’s have different mechanisms of treatment, and hasn’t seen any indication in the data that Harvoni or Sovaldi might have this same problem. Goonewardene did say, however, that this warning would mean that Gilead “doesn’t have to offer as aggressive a rebate for its drugs anymore.” AbbVie took the news hard. Shares traded for $56.53 on Oct. 16 and are currently trading for $48.26. The company’s stock trend has been largely downward since July 28 when shares traded for $71.23. Gilead Sciences , however, jumped at the news. Shares traded for $101.73 on Oct. 21 and are currently trading for $107.60. For the last year, the company’s stock has been fairly volatile, trading at a low of $89.45 on Dec. 23, 2014 and a high of $122.21 on June 23, 2015.